# Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions

> **NCT00606333** · NA · TERMINATED · sponsor: **Cordis US Corp.** · enrollment: 394 (actual)

## Conditions studied

- Coronary Atherosclerosis

## Interventions

- **DEVICE:** NEVO™ Sirolimus-eluting Coronary Stent System
- **DEVICE:** Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)

## Key facts

- **NCT ID:** NCT00606333
- **Lead sponsor:** Cordis US Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2009-05
- **Final completion:** 2012-10
- **Target enrollment:** 394 (ACTUAL)
- **Why stopped:** The NEVO™ stent will not be commercialized. Cordis have decided to close the study after 3 years. This decision took the absence of safety signals into account.
- **Last updated:** 2012-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606333, "Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00606333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*